Clinical Trials Directory

We are doing this study to find out if it is better to give patients with low-risk breast cancer regional radiation therapy as part of their standard treatment after surgery or if it is better to not give radiation. Regional radiotherapy is currently the standard treatment after surgery for low-risk breast cancer but we do not know if it is necessary in all cases.

We are doing this study to find out if radiation to the axillary (armpit) lymph nodes is equally effective and causes fewer side effects than surgical removal of the lymph nodes in patients with breast cancer.

We are doing this study to test how effectively a drug called emactuzumab works to reduce tumor size in people with tenosynovial giant cell tumors (TGCT).

We are doing this study to found out if a study drug called tarlatamab is a safe and effective option for patients with extensive stage small cell lung cancer (ES SCLC). We will compare the outcomes of how people do when they get a regimen of the study combined with durvalumab versus a regimen of durvalumab on its own.

We are doing this study to find out if avelumab is a safe and effective option for triple negative metastatic breast cancer when it is combined with different anti-cancer drugs.

We are doing this study to monitor and keep track of the results when people who have HER2-positive metastatic breast cancer that has spread to the brain choose to get treatment with trastuzumab deruxtecan. This is an observational study, which means that the manner in which you are treated with this drug will not be affected by participating in the study.

We are doing this study to find out if an experimental drug called TL-895 (the study drug) is a safe and effective option for people with indolent systemic mastocytosis.

We are doing this study to understand how different factors, such as pain experiences and inflammation, may affect how acute back pain transitions to chronic back pain.